| Autor: |
Parikh RR; a Mount Sinai Beth Israel Medical Center & Mount Sinai St. Luke's-Roosevelt Hospitals, Mount Sinai Health System , Department of Radiation Oncology , New York ., Grossbard ML; b Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center , Division of Hematology-Oncology , New York ., Harrison LB; c Moffitt Cancer Center and Research Institute , Department of Radiation Oncology , Tampa , FL , and., Yahalom J; d Memorial Sloan-Kettering Cancer Center , Department of Radiation Oncology , New York , NY , USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Leukemia & lymphoma [Leuk Lymphoma] 2016 May; Vol. 57 (5), pp. 1074-82. Date of Electronic Publication: 2015 Oct 15. |
| DOI: |
10.3109/10428194.2015.1094696 |
| Abstrakt: |
The purpose of this large observational study was to examine outcomes in patients with Hodgkin lymphoma (HL) by timing to definitive chemotherapy (TTC) using standard and propensity score (PS)-adjusted Cox proportional hazards models. From 1998-2011, 56,457 patients with stage I-IV HL were studied, with a median follow-up of 6.0 years (median age=39). Median TTC was 26 days from diagnosis. The cohort of "early" (<60 days from diagnosis) TTC patients included 45,307 (80.3%) patients and "late" (≥60 days) TTC was 11,150 (19.7%). Patients were more likely to experience early TTC if they were of a younger age, at an advanced stage, with "B" symptoms, favorably insured, favorable socioeconomic status, and treated at comprehensive cancer center (all p<0.05). Ten-year overall survival for patients with early TTC was 73.2% vs. 70.0% for those with late TTC (HR=0.87; 95%CI, 0.83-0.92, p<0.0001). After PS-matching for co-variates, early TTC was not associated with overall survival (HR=0.96; 95%CI, 0.85-1.08, p=0.51). This represents the only study to evaluate overall survival by time to definitive treatment for HL. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
